Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: A single‐center study over 12 years. Issue 1 (18th October 2020)
- Record Type:
- Journal Article
- Title:
- Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: A single‐center study over 12 years. Issue 1 (18th October 2020)
- Main Title:
- Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: A single‐center study over 12 years
- Authors:
- Miyata, Eri
Kudo, Takahiro
Ikuse, Tamaki
Tokita, Kazuhide
Arai, Nobuyasu
Oka, Itsuhiro
Kyodo, Reiko
Sato, Masamichi
Hosoi, Kenji
Jimbo, Keisuke
Aoyagi, Yo
Ohtsuka, Yoshikazu
Shimizu, Toshiaki - Abstract:
- Abstract: Background: Helicobacter pylori ( H. pylori ) infection causes chronic gastritis, duodenal and to a lesser extent, gastric ulcers, and gastric cancer. Most H. pylori infections are acquired in childhood, and effective treatment of childhood infection is very important. Esophagogastroduodenoscopy (EGD) is useful for endoscopic diagnosis, mucosal tissue biopsy, and culture examination for H. pylori in children and adults. In this paper, we report results of susceptibility tests and eradication rates in H. pylori ‐positive children who underwent EGD over a 12‐year period. Materials and Methods: The subjects were H. pylori ‐positive pediatric patients who had gastrointestinal symptoms and underwent EGD in the Department of Pediatrics, Juntendo University Hospital (January 2007–December 2018). Patients underwent serum IgG antibody tests, fecal antigen tests, or urea breath tests, and subsequently, culture tests by gastric mucosal biopsy during EGD. H. pylori positivity was defined as a positive result on both tests. Patients received triple therapy for 14 days using our regimen, and eradication was assessed at 2, 6, and 12 months after therapy. Results: Forty‐five patients were H. pylori‐ positive, and the overall clarithromycin (CAM) resistance rate was 71.1 % (32/45). The CAM resistance rate for the 2013–2018 period was significantly higher than the 2007–2012 period (52.6% vs. 84.6%, P < 0.05). According to the results of the antimicrobial susceptibility test, weAbstract: Background: Helicobacter pylori ( H. pylori ) infection causes chronic gastritis, duodenal and to a lesser extent, gastric ulcers, and gastric cancer. Most H. pylori infections are acquired in childhood, and effective treatment of childhood infection is very important. Esophagogastroduodenoscopy (EGD) is useful for endoscopic diagnosis, mucosal tissue biopsy, and culture examination for H. pylori in children and adults. In this paper, we report results of susceptibility tests and eradication rates in H. pylori ‐positive children who underwent EGD over a 12‐year period. Materials and Methods: The subjects were H. pylori ‐positive pediatric patients who had gastrointestinal symptoms and underwent EGD in the Department of Pediatrics, Juntendo University Hospital (January 2007–December 2018). Patients underwent serum IgG antibody tests, fecal antigen tests, or urea breath tests, and subsequently, culture tests by gastric mucosal biopsy during EGD. H. pylori positivity was defined as a positive result on both tests. Patients received triple therapy for 14 days using our regimen, and eradication was assessed at 2, 6, and 12 months after therapy. Results: Forty‐five patients were H. pylori‐ positive, and the overall clarithromycin (CAM) resistance rate was 71.1 % (32/45). The CAM resistance rate for the 2013–2018 period was significantly higher than the 2007–2012 period (52.6% vs. 84.6%, P < 0.05). According to the results of the antimicrobial susceptibility test, we prescribed effective antibiotics, and this resulted in a primary eradication rate of 97.7%. Conclusions: We suggest that antimicrobial susceptibility testing can significantly improve rates of primary eradication of H. pylori infection. … (more)
- Is Part Of:
- Helicobacter. Volume 26:Issue 1(2021)
- Journal:
- Helicobacter
- Issue:
- Volume 26:Issue 1(2021)
- Issue Display:
- Volume 26, Issue 1 (2021)
- Year:
- 2021
- Volume:
- 26
- Issue:
- 1
- Issue Sort Value:
- 2021-0026-0001-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2020-10-18
- Subjects:
- Helicobacter -- Periodicals
Helicobacter infections -- Periodicals
Stomach -- Diseases -- Periodicals
616.3301405 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1523-5378 ↗
http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=hel ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/hel.12764 ↗
- Languages:
- English
- ISSNs:
- 1083-4389
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4285.102500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21824.xml